These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17343427)

  • 1. Poisons centres and the reporting of adverse drug events: the case for further development.
    Volans GN; Karalliedde L; Wiseman HM
    Drug Saf; 2007; 30(3):191-4. PubMed ID: 17343427
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse events related to medications identified by a Canadian poison centre.
    Ackroyd-Stolarz SA; MacKinnon NJ; Murphy N; Gillespie E; Zed PJ
    J Popul Ther Clin Pharmacol; 2011; 18(2):e250-6. PubMed ID: 21576730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outliers and patients with adverse drug reactions.
    Edwards IR
    Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
    [No Abstract]   [Full Text] [Related]  

  • 4. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacovigilance activities in Nepal.
    Palaian S; Mohamed Ibrahim MI; Mishra P; Alam K; Shankar PR; Thapa BB
    Drug Saf; 2010 Oct; 33(10):889-90. PubMed ID: 20812773
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting of adverse drug reactions by poison control centres in the US.
    Chyka PA; McCommon SW
    Drug Saf; 2000 Jul; 23(1):87-93. PubMed ID: 10915034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' role in reporting adverse drug reactions.
    van Grootheest K; de Jong-van den Berg L
    Expert Opin Drug Saf; 2004 Jul; 3(4):363-8. PubMed ID: 15268652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving postapproval drug safety surveillance: getting better information sooner.
    Hennessy S; Strom BL
    Annu Rev Pharmacol Toxicol; 2015; 55():75-87. PubMed ID: 25292435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing an optimal approach to global drug safety.
    Balkrishnan R; Furberg CD
    J Intern Med; 2001 Oct; 250(4):271-9. PubMed ID: 11576315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication errors: pharmacovigilance centres in detection and prevention.
    Bencheikh RS; Benabdallah G
    Br J Clin Pharmacol; 2009 Jun; 67(6):687-90. PubMed ID: 19594539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety monitoring.
    Ruck B; Marcus S; Kashani J; Vassilev Z
    JAMA; 2006 Oct; 296(13):1590; author reply 1590. PubMed ID: 17018803
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential surveillance for drug safety in a regulatory environment.
    Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 19. Better reporting of adverse drug reactions.
    Abrutyn E
    Ann Intern Med; 1985 Feb; 102(2):264-5. PubMed ID: 3966766
    [No Abstract]   [Full Text] [Related]  

  • 20. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.